Hold2-5 weeks
Entry$38.36Now$34.40PnL-10.32%
80%
confidence
Angle Three positive Phase 3 DT120 reads now shift the setup from data risk to the FDA filing path.
DFTX’s latest Panorama Phase 3 GAD data hit primary and key secondary endpoints, with a 5.1-point placebo-adjusted anxiety-score improvement and effects visible by Day 2 [#31, #33]. The stronger why-now is that the third Phase 3 win moves DT120 toward an FDA submission, with analysts describing a clearer regulatory pathway and filings for two indications [#7, #28, #42].
HOLD AI Status: DFTX sits in choppy action below the 20-day EMA while oversold stochastics and lower-band Bollinger positioning keep the DT120 FDA-path thesis on a watchful footing.
Trend remains mixed with ADX near 11 and the close about 5% under the 20-day EMA at 36.46, though weekly price still holds above the 50-week SMA and RSI sits near 50. Momentum and stochastics lanes lean constructive with RSI near 40, %K/%D in the low 20s, and Bollinger %B at 0.19 hugging the lower band amid 19% bandwidth. MACD histogram is slightly negative on the daily but the fundamental setup—three Phase 3 wins and a Q4 FDA meeting—still frames this as consolidation rather than a broken story.
Triangulation
Indicators as of Oct 15, 2026 12:15 PM PT
| Trend | WATCHING | MAs mixed · ADX 11.3 chop · -5.6% vs EMA20 · close<EMA20 |
| Momentum | HOLD | RSI 39.1 · RSIw 55.2 · hist -0.12 · MACD<signal |
| Stochastics | HOLD | %K/22 · %D/27 |
| Bollinger | HOLD | %B 0.17 · lower band · BW 19.3% · ATR 5.8% |
| Weekly | WATCHING | RSIw 50.0 · RSI<RSI-SMA · hist -1.63 · close>SMA50 |
| Price action | WATCHING | 20d 19% · 52w 61% · lower highs (3) |
| Volume | HOLD | 0.78x avg · OBV ↓ |
| Position | CAUTION | PnL -10.27% · peak +5.16% · dd -14.32% · 19d held |
